When was Alamar Biosciences founded?

Alamar Biosciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Alamar Biosciences located?

Alamar Biosciences is headquartered in Fremont, United States.

Who is the current CEO of Alamar Biosciences?

Yuling Luo of Alamar Biosciences. They have also founded 1 company.

How many employees does Alamar Biosciences have?

As of Jul 31, 2026, the latest employee count at Alamar Biosciences is 239.

Is Alamar Biosciences a funded company?

Alamar Biosciences is a funded company, having raised a total of $250M across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 01, 2020.

When was the latest funding round of Alamar Biosciences?

Alamar Biosciences' latest funding was a $***** Series C round on Jan 12, 2026, with participation from 4 investors.

Where does Alamar Biosciences rank among its competitors?

Alamar Biosciences ranks 1st amongst 31 active competitors, of which 7 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Alamar Biosciences, which secured $50M in Jan, 2026.

Who are the top competitors of Alamar Biosciences?

Alamar Biosciences' top competitors include Glympse Bio, Crescendo Bioscience and Seahorse Bioscience. Among them, Alamar Biosciences secured the most recent funding round in January, 2026.

Alamar Biosciences - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. The company's proprietary NULISA Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. Applications include clinical assay development, biomarker discovery and validation, and drug development.

Website: alamarbio.com
Social
Email ID: *****@alamarbio.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Fremont, United States

Stage

Public

Total Funding

$250M in 4 rounds

Latest Funding Round

Series C, Jan 12, 2026, $*****

Investors

Sands Capital & 8 more

Ranked

1^st among 31 active competitors

Employee Count

239 as on Jul 31, 2026

Similar Companies

Glympse Bio & 53 more

Exit Details

Public

View Alamar Biosciences' full profile

Alamar Biosciences got listed on Apr 17, 2026.

Click here to take a look at Alamar Biosciences's IPO in detail

Alamar Biosciences has raised a total funding of $250M over 4 rounds. Its first funding round was on Jul 01, 2020. Its latest funding round was a Series C round on Jan 12, 2026 for $*****. 4 investors participated in its latest round. Alamar Biosciences has 9 institutional investors.

Here is the list of recent funding rounds of Alamar Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 12, 2026	9005047	Series C	5516576	9581163	1322038	6783182
Feb 26, 2024	1746546	Series C	1456803	9870411	9499346	3185458
Sep 08, 2021	4433496	Series B	9758789	4240797	Sherpa Healthcare Partners	Morningside & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Alamar Biosciences's funding rounds and investors

The founders of Alamar Biosciences are Yuling Luo and Steve Chen. Yuling Luo is the CEO of Alamar Biosciences.

Here are the details of Alamar Biosciences' key team members:

Yuling Luo: Co-Founder & CEO of Alamar Biosciences and founder of 1 other company.
Steve Chen: Co-Founder of Alamar Biosciences.
Contact Info: 1 email address

View details of Alamar Biosciences's Founder profiles and Board Members

Alamar Biosciences' employee count trend

Alamar Biosciences has 239 employees as of Jul 26. Here is Alamar Biosciences's employee count trend over the years:

Employee count trend for Alamar Biosciences

Uncover Alamar Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alamar Biosciences include Glympse Bio, Crescendo Bioscience and Seahorse Bioscience. Here is the list of Top 10 competitors of Alamar Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alamar Biosciences 2018, Fremont (United States), Public	Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels	$250M	T. Rowe Price, Samsara BioCapital & 7 others	66/100
2nd	Glympse Bio 2015, Cambridge (United States), Acquired	Provider of noninvasive and predictive monitoring of multiple human diseases	$79.4M	Polaris Partners, Section 32 & 18 others	48/100
3rd	Crescendo Bioscience 2002, San Francisco (United States), Acquired	CLIA Laboratory focused on autoimmune and inflammatory diseases	$122M	Calibrium, Kleiner Perkins & 7 others	47/100
4th	Seahorse Bioscience 2000, Boston (United States), Acquired	Analytical instruments, lab supplies, and services for scientific research and diagnostics	$28.8M	Life Sciences Partners, EQT & 10 others	43/100
5th	Harmonic Discovery 2021, New York City (United States), Seed	Developer of kinase inhibitor drugs for oncology	$8.12M	Innovation Endeavors, Y Combinator & 3 others	42/100
6th	Guardant Health AMEA 2018, Singapore (Singapore), Acquired	Provider of a technology platform for the diagnosis of cancer using AI	-	-	39/100
7th	Carna Biosciences 2003, Kobe (Japan), Public	Develops kinase assay kits and provides services in protein characterization	-	Japan Asia Investment, MBL Venture Capital ... & 4 others	38/100
8th	STAT Diagnostica 2010, Barcelona (Spain), Series C	Provider of a diagnostic platform for molecular diagnostics and immunoassays	$53.7M	Gilde Healthcare, Ysios Capital & 8 others	38/100
9th	Ammulifetech.com 2015, Wuhan (China), Series C	Developer of smart devices for screening tumors	$15.2M	CCB International, Wuhan Gaoke State-owned Holding Group ... & 1 others	37/100
10th	Phinomics 2021, San Carlos (United States), Funding Raised	Developer of a genome-based technology to detect cancer	-	HHS, Silicon Catalyst Angels	37/100